NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$43.36

+1.06 (+2.51 %)

(As of 10/29/2020 12:00 AM ET)

Add

Compare

Today's Range

$40.86

Now: $43.36▼

$43.86

50-Day Range

$36.69

MA: $39.74▼

$43.27

52-Week Range

$14.16

Now: $43.36▼

$50.49

Volume122,340 shs

Average Volume207,481 shs

Market Capitalization$1.74 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.36

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

1.4 Analyst's Opinion

Consensus Rating
Y-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.71, Y-mAbs Therapeutics has a forecasted upside of 3.1% from its current price of $43.36.
Amount of Analyst Coverage
Y-mAbs Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Y-mAbs Therapeutics has received 81 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Y-mAbs Therapeutics has received 90 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Y-mAbs Therapeutics has received 52.63% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote “Outperform” if you believe YMAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Y-mAbs Therapeutics does not currently pay a dividend.
Dividend Growth
Y-mAbs Therapeutics does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Y-mAbs Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,594,787.00 in company stock.
Percentage Held by Insiders
38.40% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.20% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($3.25) to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Y-mAbs Therapeutics is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Y-mAbs Therapeutics is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Y-mAbs Therapeutics has a P/B Ratio of 8.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.29 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:YMAB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.ymabs.com

Phone646-885-8505

Employees32

Debt

Debt-to-Equity RatioN/A

Current Ratio10.40

Quick Ratio10.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.01 per share

Price / Book8.65

Profitability

EPS (Most Recent Fiscal Year)($2.30)

Net Income$-81,030,000.00

Net MarginsN/A

Return on Equity-74.98%

Return on Assets-66.70%

Miscellaneous

Outstanding Shares40,015,000

Market Cap$1.74 billion

Next Earnings Date11/11/2020 (Estimated)

OptionableNot Optionable

$43.36

+1.06 (+2.51 %)

(As of 10/29/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

How has Y-mAbs Therapeutics' stock been impacted by Coronavirus?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, YMAB stock has increased by 88.7% and is now trading at $43.36.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Y-mAbs Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Y-mAbs Therapeutics.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Y-mAbs Therapeutics.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) issued its earnings results on Thursday, August, 6th. The company reported ($1.01) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.69) by $0.32.
View Y-mAbs Therapeutics' earnings history.

What price target have analysts set for YMAB?

9 brokers have issued 1-year price objectives for Y-mAbs Therapeutics' shares. Their forecasts range from $39.00 to $52.00. On average, they anticipate Y-mAbs Therapeutics' share price to reach $44.71 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 3,260,000 shares, an increase of 11.6% from the September 30th total of 2,920,000 shares. Based on an average daily trading volume, of 151,200 shares, the short-interest ratio is presently 21.6 days. Approximately 13.2% of the shares of the stock are short sold.
View Y-mAbs Therapeutics' Short Interest.

Who are some of Y-mAbs Therapeutics' key competitors?

Some companies that are related to Y-mAbs Therapeutics include Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Perrigo (PRGO), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Emergent BioSolutions (EBS), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Allakos (ALLK), Turning Point Therapeutics (TPTX) and Evotec (EVTCY).
View all competitors.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:

Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.46%), DekaBank Deutsche Girozentrale (0.03%), HighMark Wealth Management LLC (0.01%), Nisa Investment Advisors LLC (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San and Thomas Gad.
View institutional ownership trends for Y-mAbs Therapeutics.

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, HighMark Wealth Management LLC, Nisa Investment Advisors LLC, and Pacer Advisors Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, and Pedro Claus Juan Moller-San.
View insider buying and selling activity for Y-mAbs Therapeutics.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $43.36.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.74 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings